- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004335
Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle
OBJECTIVES: I. Evaluate the sleep-entrained patterns of gonadotropin-releasing hormone (GnRH) and sex steroid secretion in normal and hypogonadal children.
II. Examine the acute effects of sex steroids on the sleep-entrained patterns of GnRH secretion in pubertal children and normal adults, either by stimulation of endogenous production with pulsatile injection or by intravenous infusion of GnRH.
III. Examine the role of endogenous opioids by means of opioid receptor blockade in the sex steroid regulation of GnRH secretion in pubertal children and normal adults.
Study Overview
Status
Conditions
Detailed Description
PROTOCOL OUTLINE: This project involves several clinical protocols that study the regulation and role of pulsatile gonadotropin-releasing hormone (GnRH) secretion.
Studies include dynamic and repeated stimulation tests of pulsatile GnRH; plasma luteinizing hormone, follicular-stimulating hormone, testosterone (T), estradiol (E2), and GnRH measurements at cyclic and episodic intervals; and evaluation of adrenal androgen patterns.
Circadian rhythms of GnRH secretion are monitored during sleep and awake hours. Growth hormone secretory patterns and responses to provocative stimuli are studied as clinically indicated.
Selected participants undergo an assessment of pituitary responsiveness following T, E2, and/or naloxone infusions. The suppressive effects of E2 are also studied during the early follicular phase of the menstrual cycle.
Endocrinologically normal children and normal adult men and women are also studied.
Study Type
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Health Systems
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Suspected or proven hypothalamic-pituitary-gonadal dysfunction, i.e.: Significant short stature and possible hypopituitarism Delayed adolescence Precocious puberty Isolated growth hormone deficiency (IGHD)Primary hypogonadism
- Women are also studied, including those with the following disorders: Infertility Oligo- or amenorrhea Hirsutism
--Patient Characteristics--
- Age: 7 to 16 (18 to 35 for women and volunteers)
- Other: No pregnant or nursing women No prisoners Not in neuropsychiatric institute or other facility for mental illness
Study Plan
How is the study designed?
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Carol M. Foster, University of Michigan
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 199/11894
- UMMC-271
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Precocious Puberty
-
AbbVieCompletedCentral Precocious Puberty (CPP)United States, Puerto Rico
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedCentral Precocious Puberty (CPP)Italy
-
Children's Hospital of Fudan UniversityTerminated
-
Children's Hospital of Fudan UniversityNot yet recruiting
-
Daewoong Pharmaceutical Co. LTD.Recruiting
-
Endo PharmaceuticalsCompletedCentral Precocious Puberty
-
Tolmar Inc.CompletedPrecocious Puberty, CentralUnited States, Canada, Argentina, Chile, Mexico, New Zealand
-
University of MinnesotaEndo Pharmaceuticals; Atlantic Center for Research; Goryeb Children's HospitalTerminatedCentral Precocious PubertyUnited States
-
Debiopharm International SAActive, not recruitingCentral Precocious PubertyUnited States, Argentina, Brazil, Chile, Mexico
-
Foresee Pharmaceuticals Co., Ltd.QPS Holdings LLC; Changchun GeneScience Pharmaceutical Co., Ltd.Active, not recruitingPuberty; Precocious, CentralUnited States, China, Taiwan, Puerto Rico